trans-3-hexenoyl is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-09. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
=== Fermentation-produced chymosin === Because of the above imperfections of microbial and animal rennets, many producers sought other replacements of rennet. With genetic engineering it became possible to isolate rennet genes from animals and introduce them into certain bacteria, fungi, or yeasts to make them produce recombinant chymosin during fermentation. The genetically modified microorganism is killed after fermentation and chymosin isolated from the fermentation broth, so that the fermentation-produced chymosin (FPC) used by cheese producers does not contain a GMO or any GMO DNA. FPC is identical to chymosin made by an animal, but is produced in a more efficient way. FPC products have been on the market since 1990 and, because the quantity needed per unit of milk can be standardized, are commercially viable alternatives to crude animal or plant rennets, as well as generally preferred to them in industrial production. Originally created by biotechnology company Pfizer, FPC was the first artificially-produced enzyme to be registered and allowed by the US Food and Drug Administration. In 1999, about 60% of US hard cheeses were made with FPC, which thereafter made up to 80% of the global market share for rennet. By 2017, FPC had 90% of the global market share for rennet. By 2021, animal rennet still found use in some traditional or designated European cheeses but FPC covered 80-90% of the market in the US and UK. The most widely used FPC is produced either by the fungus Aspergillus niger and commercialized under the trademark CHY-MAX by the Danish company Chr.
== History == Xylazine was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Leverkusen, West Germany. In human trials xylazine was found to depress the central nervous system leading to the discontinuation of further research for its use in humans and it was instead marketed as a veterinary sedative, starting in the late 1960s. Xylazine proved popular and in the 1970s became one of the most common large animal sedatives. Xylazine's muscle relaxant effect inhibits the transmission of neural impulses in the central nervous system. In 1981 a study discovered that the cause sedation was due to xylazine's effect on the α2-adrenergic receptor. This led to the development of other α2-adrenergic receptor agonists such as detomidine, medetomidine, dexmedetomidine, and romifidine. In the United States, xylazine was approved by the FDA only for veterinary use as a sedative, analgesic, and muscle relaxant in dogs, cats, horses, elk, fallow deer, mule deer, sika deer, and white-tailed deer. In scientific research using animal experiments, xylazine is a component of the most common anesthetic, ketamine-xylazine (see: Rodent cocktail), to anesthetize rats, mice, hamsters, and guinea pigs. Xylazine has not previously been a controlled substance; however, due to illicit abuse, legislative restrictions have been proposed in multiple countries. Xylazine was made a class C drug in the UK on 15 January 2025.
Reports of widespread adulteration of Chinese animal feed with melamine have raised the issue of melamine contamination in the human food supply both in China and abroad. In April 2007, the U.S. Food and Drug Administration (FDA) subjected all vegetable proteins imported from China, intended for human or animal consumption, to detention without physical examination, including: wheat gluten, rice gluten, rice protein, rice protein concentrate, corn gluten, corn gluten meal, corn by-products, soy protein, soy gluten, proteins (includes amino acids and protein hydrolysates), and mung bean protein. Officials from the FDA and U.S. Department of Agriculture said that between 2.5 and 3 million Americans had consumed chickens that had consumed feed containing contaminated vegetable protein from China. Reports that melamine has been added as a binder in animal feed manufactured in North America raised the possibility that harmful melamine contamination might not be limited to China. In 2008, Sanlu Group had to recall baby formula because it was contaminated with melamine. Around 294,000 babies in China became ill after drinking the milk; at least six died. As of July 2010, Chinese authorities were still reporting some seizures of melamine-contaminated dairy product in some provinces, though it was unclear whether these new contaminations constituted wholly new adulterations or were the result of illegal reuse of material from the 2008 adulterations.
== History == Peak Scientific was established by its founder and current chairman Robin MacGeachy in 1992 originally operating as an air compressor distributor until 1997 when the company was registered to manufacture gas generators on a 10,000 square foot facility at Inchinnan. It was not until 2004 when Robin MacGeachy fully acquired the business. Timeline 1992 – Business initially established as a distributor of air compressors 1997 – Peak Scientific established to manufacture gas generators 2005 – First international office opens in North America 2007 – India office opens 2008 – Africa office opens 2010 – Mexico, China and Hong Kong offices open 2011 – Australia office opens 2012 – Offices in Germany, Brazil, Japan and Singapore open 2013 – Offices in Canada, France and Spain open 2015 – New offices open in India and Abu Dhabi 2016 – Third office in India opens 2017 – Business is registered in Ireland and Vietnam 2018 – Office in Korea opens
Sources: en.wikipedia.org
The main result that is measured at the end of a study to see if a given treatment worked (e.g., the number of deaths or the difference in survival between the treatment group and the control group). What the primary endpoint will be is decided before the study begins. (NCI) Prospective
=== By individual compound === This list includes notable compounds representative of most of the structural variations that have been explored in this series, but is by no means exhaustive. Many derivatives invented for scientific study into the structure-activity relationships of 5-HT2 receptor agonists have never appeared as designer drugs, while conversely some derivatives that have appeared as designer drugs are structurally novel and of unknown pharmacological activity (e.g. C30-NBOMe, 5-APB-NBOMe).
If successful, such a blood substitute could save many lives, particularly in trauma where massive blood loss results. Recent research has also explored blood-filtration and pathogen-removal technologies that could allow contaminated blood collected during trauma or surgery to be cleaned and safely returned to the patient through autologous transfusion, potentially reducing reliance on donor blood in emergency settings. For example, intraoperative cell salvage systems are already used in some surgical settings to collect, filter, and reinfuse a patient's own blood during procedures with significant blood loss. Hemopure, a hemoglobin-based therapy, is approved for use in South Africa and has been used in the United States on a case-by-case basis through the emergency Investigational New Drug (IND) process. In the mean time, bloodless medicine emerged as a new discipline in blood transfusion treatment paradigm to fill these gaps. Bloodless medicine employs various strategies to reduce the risk in the surgical treatment of "bloodless patients' using techniques like erythropoiesis-stimulating agents, autologous blood salvage, and minimizing blood loss during surgery.
Phillips and Connelly had an agreement that distribution of MET-Rx would be controlled, and that they would not sell it to retail outlets in order to keep supply low during the period of high demand created by the advertisements in Muscle Media 2000. Connelly however, had other ideas and began selling it to mainstream distributors and department stores. Phillips believed this move lessened its appeal to bodybuilders, and destroyed the "mystique" of the product. The two parted ways, and as part of the settlement, Phillips was legally bound not to mention the name of MET-Rx in his magazines (thereafter he would refer to it as "the leading brand"). But by then Phillips had his eye on another venture that would eclipse MET-Rx altogether – EAS.
MFAP4 (microfibril-associated glycoprotein 4) is an extracellular matrix protein encoded by the MFAP4 gene. It is part of the MFAP family of proteoglycans, which are involved in cell adhesion, intercellular interactions and the assembly and/or maintenance of elastic fibres. MFAP4 is known to co-localise at sites rich in elastic fibres and is thought to interact with several proteins including FBN1, FBN2, tropoelastin and desmosine. It has a relatively non-specific tissue expression pattern, with higher levels observed in organs such as the lungs and vasculature.
Sources: en.wikipedia.org
== Structure and function == Motor nerve fibers transduce signals from the CNS to peripheral neurons of proximal muscle tissue. Motor nerve axon terminals innervate skeletal and smooth muscle, as they are heavily involved in muscle control. Motor nerves tend to be rich in acetylcholine vesicles because the motor nerve, a bundle of motor nerve axons that deliver motor signals and signal for movement and motor control. Calcium vesicles reside in the axon terminals of the motor nerve bundles. The high calcium concentration outside of presynaptic motor nerves increases the size of end-plate potentials (EPPs).
Anaerobic respiration is respiration using electron acceptors other than molecular oxygen (O2) in its electron transport chain. In aerobic organisms, electrons are shuttled to an electron transport chain, and the final electron acceptor is oxygen. Molecular oxygen is an excellent electron acceptor. Anaerobes instead use less-oxidizing (in either thermodynamic or kinetics sense) substances such as nitrate (NO−3), fumarate (C4H2O2−4), sulfate (SO2−4), or elemental sulfur (S), among others. These terminal electron acceptors have smaller reduction potentials than O2. Less energy per oxidized molecule is released. Therefore, anaerobic respiration is less efficient than aerobic.
The Metropolitan Transportation Authority plans to bring Metro-North Railroad commuter trains to Penn Station as part of its Penn Station Access project. The East Side Access project, which was completed in 2023, has freed up track and platform space at Penn Station by redirecting some LIRR trains from Penn Station to Grand Central Madison. This new capacity, as well as track connections resulting from the East Side Access project, will allow Metro-North trains on the New Haven Line to run to Penn Station via Amtrak's Hell Gate Bridge. Four new local Metro-North stations in the Bronx are planned as part of this project, at Co-op City, Morris Park, Parkchester/VanNest, and Hunts Point. The MTA also proposes a second service from the Metro-North's Hudson Line to Penn Station using Amtrak's West Side Line in Manhattan. The Penn Station Access project would provide direct rides from Connecticut, Westchester County, the Lower Hudson Valley, and the Bronx to West Midtown; ease reverse-commuting from Manhattan and the Bronx to Westchester County, the Lower Hudson Valley, and Connecticut; and provide transportation service to areas of the Bronx without direct subway service.
These metabolic interferences lead to death from multi-system organ failure, probably from necrotic cell death, not apoptosis. A post mortem reveals brick red colored mucosa, due to severe hemorrhage. Although arsenic causes toxicity, it can also play a protective role.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。